Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Ponce Aix, S., Paz-Ares, L., Chiu, C., Park, K., Novello, S., Nadal, E., Imamura, F., Yoh, K., Shih, J., Au, K. H., Moro-Sibilot, D., Enatsu, S., Zimmermann, A., Frimodt-Moller, B., Visseren-Grul, C., Reck, M., & , (2019). ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, 20(12), 1655–1669. http://access.bl.uk/ark:/81055/vdc_100098053389.0x000014